Ultragenyx Pharmaceutical Inc.
For the period ended Jun 30, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 5, 2026
RARE$16.41+6.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In millions, except per share amounts)
| June 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $125 | $421 |
| Marketable securities | 167 | 259 |
| Accounts receivable, net | 200 | 158 |
| Inventory | 59 | 52 |
| Prepaid expenses and other assets | 55 | 61 |
| Total current assets | 606 | 951 |
| Property, plant, and equipment, net | 235 | 244 |
| Marketable securities | 144 | 57 |
| Intangible assets, net | 172 | 176 |
| Goodwill | 44 | 44 |
| Other assets | 63 | 60 |
| Total assets | $1,264 | $1,532 |
| LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS' EQUITY (DEFICIT) | ||
| Current liabilities: | ||
| Accounts payable | $39 | $31 |
| Accrued liabilities | 221 | 265 |
| Liabilities for sales of future royalties | 76 | 69 |
| Other liabilities | 15 | 19 |
| Total current liabilities | 351 | 384 |
| Deferred tax liabilities | 30 | 30 |
| Liabilities for sales of future royalties | 1,126 | 1,147 |
| Other liabilities | 41 | 44 |
| Total liabilities | 1,548 | 1,605 |
| Noncontrolling interest | 7 | 7 |
| Stockholders’ deficit: | ||
| Preferred stock, par value of $0.001 per share—25.0 shares authorized; nil outstanding in 2026 and in 2025 | — | — |
| Common stock, par value of $0.001 per share—250.0 shares authorized; outstanding—98.6 in 2026 and 96.6 in 2025 | — | — |
| Treasury stock, at cost, 0.3 shares in 2026 and 0.2 shares in 2025 | (10) | (8) |
| Deferred compensation obligation | 10 | 8 |
| Additional paid-in capital | 4,518 | 4,451 |
| Accumulated other comprehensive income | — | 1 |
| Accumulated deficit | (4,809) | (4,532) |
| Total stockholders’ deficit | (291) | (80) |
| Total liabilities, noncontrolling interest and stockholders’ deficit | $1,264 | $1,532 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.